Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 3,057	$ 3,837	$ 6,160	$ 5,513
Research and development
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	994	1,285	1,808	1,401
General and administrative
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 2,063	$ 2,552	$ 4,352	$ 4,112